Tumor-associated antigens from autologous tumor lysate (TAA-ATL) (TAA-ATL)

Tumor-associated antigens from autologous tumor lysate represent a personalized approach to cancer immunotherapy, where a patient's own tumor tissue is surgically resected and processed to create a mixture of antigens unique to that individual's malignancy. This lysate contains a broad repertoire of both shared tumor-associated antigens (TAAs) and patient-specific neoantigens, which helps to overcome tumor heterogeneity and reduce the risk of immune escape. The primary biological function of these antigens in a therapeutic context is to serve as the substrate for antigen-presenting cells, such as dendritic cells, which process and present them to the immune system to elicit a robust, polyclonal T-cell response. By activating both CD8+ cytotoxic T lymphocytes and CD4+ helper T cells, this approach aims to induce long-lasting immunological memory and targeted destruction of tumor cells. Clinically, autologous tumor lysates are most commonly used in the production of dendritic cell vaccines, such as DCVax-L for glioblastoma, where they have shown potential in extending overall survival in selected patient populations. While generally well-tolerated, safety concerns include localized injection site reactions and, in the case of central nervous system tumors, potential complications like intracranial edema.

Other names

Autologous tumor lysateATLPatient-specific tumor antigensWhole tumor lysateTAA-ATL

Induction of a polyclonal T-cell response against a broad spectrum of patient-specific tumor antigens.